Upcoming Phase 3 Readouts: Key Catalysts to Watch in 2026

On August 5, 2026, we focus on three critical phase 3 readouts that could shape the market. With the first expected in December 2026, these clinical trial results could sway investor sentiment and stock performance for the involved companies. Our analysis explores the specifics of each drug and its potential implications for their respective indications.

The full Phase 2 and Phase 3 readouts to watch

MN-166: A Potential Breakthrough for Amyotrophic Lateral Sclerosis

MN-166, in Phase 2, is being developed by MNOV for Amyotrophic Lateral Sclerosis (ALS) with results anticipated in April 2027. Leading up to this readout, MNOV’s stock has fallen by 9.7%, showing market skepticism. ALS presents significant unmet medical needs, and positive data could dramatically change perceptions. The Phase 2 readout will likely emphasize safety and efficacy metrics. Investors should watch closely, given the high stakes. If results disappoint, MNOV’s stock might drop further. On the other hand, positive results could spark a substantial rebound, especially given the urgency in ALS treatment development.

MN-001: Aiming to Address Type 2 Diabetes

The Phase 2 readout for MN-001, also from MNOV, is scheduled for December 31, 2026. The drug targets Type 2 Diabetes, affecting millions globally. Like MN-166, the stock has dipped 9.7% before this trial. This moment is crucial for MNOV; successful data could make MN-001 a contender in a crowded market. However, risks are high, given the robust current treatment landscape. Negative results could further dampen investor confidence. MN-001 has the potential to alter its market trajectory, but it hinges heavily on the upcoming trial results.

CTX-009: Targeting Biliary Tract Cancer

CTX-009, combined with Paclitaxel, is in Phase 2 targeting Biliary Tract Cancer, with results expected on December 1, 2026. CMPX’s stock has dropped 13.5% as anticipation builds. Biliary Tract Cancer is tough to treat, and this combination therapy could offer new hope. Investors need to be cautious; a negative readout could lead to further declines, while positive results might renew interest. The trial outcomes could be pivotal for CMPX’s future, especially given the high unmet needs in this indication.

Monitoring Gated Items: Upcoming Catalysts to Consider

Beyond the phase 2 readouts mentioned, several gated items deserve attention. Sonelokimab from MLTX will provide data for Hidradenitis Suppurativa on September 28, 2026. This indication has gained interest, and positive results could significantly boost MLTX’s standing. DBV712, targeting allergies, is set for November 2026, and its outcome could dramatically affect DBVT’s stock. These upcoming trial results will be crucial in shaping market expectations and investor strategies. Tracking these developments closely is recommended, as they could lead to substantial stock volatility.

The Importance of Cash Runway and Dilution Risks

As we assess these phase 3 readouts, considering the financial health of the companies is crucial. Many firms with upcoming results face pressure regarding their cash runway. For instance, three companies we’re watching have less than a year of cash remaining. A complete response letter (CRL) could force them to raise funds at unfavorable prices, leading to significant dilution for current shareholders. This financial aspect adds a layer of risk to the impending clinical trial results. Investors should evaluate financials alongside clinical prospects to make informed decisions.

Investor Sentiment and Market Reactions

Sentiment surrounding these phase 3 readouts is key to understanding market dynamics. Positive trial results can lead to sharp price increases, while negative outcomes can trigger steep declines. For example, MNOV and CMPX’s recent stock performances suggest caution as they prepare for their readouts. Investors should stay alert and ready to react to the trial results. The market's immediate reaction will depend on the perceived significance of the data and its implications for treatment options. Having a strategy in place to handle potential volatility is recommended.

The bottom line

The upcoming phase 3 readouts present significant opportunities and risks for investors. Staying informed and prepared is crucial as we approach these pivotal moments.